Analysts’ Recent Ratings Updates for Catalyst Pharmaceuticals (CPRX)

A number of research firms have changed their ratings and price targets for Catalyst Pharmaceuticals (NASDAQ: CPRX):

• 5/18/2026 – Catalyst Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 5/9/2026 – Catalyst Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Catalyst Pharmaceuticals was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $31.50 price target on the stock, down from $35.00.
• 5/7/2026 – Catalyst Pharmaceuticals was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 5/7/2026 – Catalyst Pharmaceuticals was given a new $32.00 price target by Stephens.
• 5/7/2026 – Catalyst Pharmaceuticals was downgraded by Robert W. Baird from “strong-buy” to “hold”.
• 5/7/2026 – Catalyst Pharmaceuticals was downgraded by Stephens from “overweight” to “equal weight”.
• 3/27/2026 – Catalyst Pharmaceuticals had its “buy (b-)” rating reaffirmed by Weiss Ratings.
• 3/27/2026 – Catalyst Pharmaceuticals was upgraded by Cantor Fitzgerald to “strong-buy”.
• 3/25/2026 – Catalyst Pharmaceuticals was upgraded by Truist Financial Corporation to “strong-buy”.

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).